Switching to aromatase inhibitor may lower risk of recurrence

A recent study, presented at the prestigious 31st Annual  San Antonio Breast Cancer Symposium, has found that women who switched to an aromatase inhibitor (AI) after two to three years of Tamoxifen lowered their risk of recurrence.  These results relate to post-menopausal women with early stage, estrogen receptor positive breast cancer.

If you wish to read more on this study please click here